HORMONE REPLACEMENT IN MENOPAUSAL WOMEN

我们正在研究30名65-75岁的女性， 恒定的口服雌激素/低剂量的每日孕酮（ERT）和30名年龄匹配的 骨丢失（DEXA）和骨生化指标的BLSA对照 转换，血脂，人体测量指标，DEXA身体测量 脂肪和阴道成熟指数。 情绪，雌激素的症状 缺乏和激素替代疗法的副作用进行评估。 轻微的乳房压痛和阴道出血是唯一的不良反应 观察到的效果。 接受治疗的女性总体下降了3.8%， 胆固醇（NS），HDL增加16%，LDL降低17% (both p<0.001），并且血浆甘油三酯没有显著变化。 DEXA 扫描显示体脂百分比降低（p<0.03）， 瘦体重（P<0.03）和骨密度（腰椎+7%; 股骨粗隆+9%，均P<0.01）。 数据显示，老年人的ERT 绝经后妇女改善代谢功能， 身体组成的有利变化。 我们发现有利的风险/获益 老年绝经后妇女的ERT比率。

We are studying 30 women 65-75 years of age treated for 2 y with constant oral estrogen/low dose daily progestin (ERT) and 30 age-matched BLSA controls for bone loss (DEXA) and biochemical indices of bone turnover, plasma lipids, anthropometric indices, DEXA measures of body fat, and vaginal maturation indices. Mood, symptoms of estrogen deficiency, and side effects of hormone replacement therapy are assessed. Minor breast tenderness and vaginal bleeding are the only adverse effects observed. Treated women showed a 3.8% decrease in total cholesterol (NS) with a 16% increase in HDL and a 17% decrease in LDL (both p<0.001), and no significant change in plasma triglycerides. DEXA scans revealed a decrease in percent body fat (p<0.03) and increases in lean body mass (p<0.03) and bone mineral density (lumbar spine +7%; femoral trochanter +9%, both p<0.01). Data suggest that ERT in older postmenopausal women improves metabolic function and results in favorable changes in body composition. We find a favorable risk/benefit ratio for ERT in older postmenopausal women.